Drug Approval | October 01, 2025
AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The approval is supported by results from the Phase 3 SWOG 1826 trial
The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
